How To Become A Medical Consultant

Size: px
Start display at page:

Download "How To Become A Medical Consultant"

Transcription

1 CURRICULUM VITAE Page 1 of 12 Statement of Education and Qualifications Name (First, Middle, Last) ANTONIO CASADO HERRAEZ Academic Qualification(s) (e.g. MD, MBBS, Medical License Number, etc) MD, PhD Current place of work. Address (Name of Institution, Street, City, Postal Code, State or Province (if applicable), Country) Department of Medical Oncology - HOSPITAL UNIVERSITARIO (CLINICO) SAN CARLOS / San Carlos University Teaching Hospital C/PROF, MARTIN LAGOS S/N, MADRID, SPAIN s: antoniocasado@telefonica.net and acasado.hcsc@salud.madrid.org Telephone Number (Country Code, Area Code, Number) / , ext and 7549 FAX Number (Country Code, Area Code, Number) Education and Training (List all Colleges, Universities and Medical Schools attended incl. postdoctoral/fellowship training, including board certification/medical license) Name and Location of Institution (City, State or Degree and Year Awarded Area of Study Province and Country) UNIVERSIDAD AUTONOMA DE MADRID, MADRID, SPAIN (*) 1983, MD MEDICINE AND SURGERY UNIVERSIDAD COMPLUTENSE DE MADRID, SPAIN (***) TRAINING IN MEDICAL ONCOLOGY: Hospital Universitario San Carlos, Madrid (**) July 2001-February 2008, PhD MEDICAL ONCOLOGY/NTER NAL MEDICINE Speciality in Medical Oncology Version 01 May 2011

2 CURRICULUM VITAE Page 2 of 12 (*) : Graduate in Surgery and Medicine from the Universidad Autónoma de Madrid. Pass with distinction. 1983: Graduated from the Universidad Autónoma de Madrid. Qualification obtained: Firstclass. (**) : Spanish National Medical Training Scheme (MIR): Internship in Medical Oncology through the national MIR system in the speciality of Medical Oncology at the Medical Oncology Service of the San Carlos University Teaching Hospital, Madrid : PhD. Four courses studied. (***) 2001: Advanced Studies Diploma (ASD). "Randomized study of two dosage levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in advanced cancer. Mark obtained: Excellent. Doctoral thesis on anorexia and cancer: Cum Laude (February 2008) onwards: Associate Professor Professional Experience (#) Position/Title Current STAFF MEDICAL ONCOLOGY DEPARTMENT / Senior Consultant ASSOCIATE PROFESSOR Name and Location of Institution (City, State or Province and Country) HOSPITAL UNIVERSITARIO CLINICO SAN CARLOS, MADRID, SPAIN UNIVERSIDAD COMPLUTENSE DE MADRID, SPAIN Dates (Start/Stop Dates as applicable) 1989-CURRENT 2005-CURRENT (#) Main areas of professional interest: gynaecological tumours, sarcomas of soft tissue and bones, breast cancer, tumours of unknown origin and supportive treatment. Services rendered include house officer at the Medical Oncology Service of the San Carlos University Teaching Hospital in Madrid from April 1st 1989, to the present. Member of the EORTC Gynaecological Cancer Group (GCG) since Secretary to the EORTC GCG from March 2003 to March Chairman to the EORTC GCG since March Member of the Soft tissue and bone sarcoma group of the EORTC since November National cooperative groups: GEICAM Group (Spanish Group for breast cancer research), since GEICO Group (Spanish Group for ovarian cancer and gynaecological tumour

3 CURRICULUM VITAE Page 3 of 12 research), since GEIS Group (Spanish Group for research into soft tissue and bone sarcoma), since 1996 (#) Other Medical Interest Member (associate) of the Spanish Society for Medical Oncology (SEOM) since 1987 and full member since 1989, to the present Member of the European Society for Medical Oncology (ESMO) since September Member of the American Society of Clinical Oncology (ASCO) from July 2000 to December Member of the European Society of Gynaecological Oncology (ESGO) since 2006.

4 CURRICULUM VITAE Page 4 of 12 Research Participation in several clinical and basic research projects on gynaecological cancers, breast cancer, soft tissue and bone sarcoma, thyroid cancer and tumours of unknown origin Participation in national and international phase I, II and III studies. Previous participation in clinical trials (Required Information for Investigators in the European Union) Indication of Trial Clinical Phase of Trial (I-IV) Role in Trial (e.g. Investigator, Sub-Investigator) Year in which trial was conducted SEVERAL TRIALS: GYNAECOLOGICAL I,II, III PI / SUB-INV 1988-CURRENT CANCER, BREAST CANCER, SOFT TISSUE AND BONE SARCOMA, THYROID CANCER Training on ICH/GCP: YES X If yes, specify below NO During Several trials Other documents evidencing experience or expertise attached: YES If yes, specify below NO X Publications in English Language Signature (if required) Date

5 CURRICULUM VITAE Page 5 of 12 Personal data Date of birth: January 18, 1959 Marital status: Married to Esther Martin and enjoying Nadia and Paula. ID card no: Home address (Street, City, Postal Code, State or Province -if applicable-, Country) C/ Las Naves nº 18, 4º - A. MADRID Spain Telephone Number Mobile phone number FAX Number (Private) Appendix. Publications: more than 80 papers co-authored and published in English language in international Journals. 1. Martín M, Díaz-Rubio E, Casado A, López Vega JM. Phase II study of carboplatin in breast cancer: Preliminary results. Seminars in Oncology 1 (Suppl 2): 23-27, Palmeiro R, Díaz-Rubio E, Martín M, González JL, Casado A, García del Muro A, López Vega JM, Lozano Setien E. Time trends of some risk factors of breast cancer. J Cancer Res Clin Oncol 1990; 116 (Suppl., Part 1): Martín M, Díaz-Rubio E, Casado A, López Vega JM. Phase II Study of Carboplatin in Breast cancer: Preliminary results. J Cancer Res Clin Oncol 1990; 116 (Suppl., Part I): Martín M, Díaz-Rubio E, González Larriba JL, Casado A, Sastre J, López-Vega JM, Almenarez J, Domínguez S. Phase II study of Ifosfamide in head and neck cancer. Cancer Chemotherapy and Pharmacology (1993): 31: Martín M, Díaz-Rubío E, Casado A, López Vega JM, Sastre J, Almenarez J. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controled trial. American Journal of Clinical Oncology 15 (3): 1992, Miguel Martín, E. Díaz-Rubio, Antonio Casado, Severina Domínguez, Javier Sastre. Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy. A study of 107 patients treated with 6 courses of FAC (5-FU, Adriamycin, cyclophosphamide) chemotherapy. The European Journal of Cancer 28: ; Miguel Martín, Eduardo Díaz-Rubio, Antonio Casado, Pedro Santabárbara, José Manuel López Vega, Encarna Adrover, Luigi Lenaz. Carboplatin: an active drug in metastatic breast cancer. Journal of Clinical Oncology 10: , 1992.

6 CURRICULUM VITAE Page 6 of García-Conde J, Lluch A, Casado A, et al. Phase II trial with Navelbine in advanced breast cancer previously untreated. Breast Cancer Res Treat 23: 142, 1992 (Abstr 52). 9. Martín M, Casado A, Lluch A*, Adrover E, Díaz-Rubio E, and García-Conde *. Preliminary results of a phase II trial of chronic oral etoposide in breast cancer. Cancer Treatment Review (1993) 19 (Supplement C), Martín M, Díaz-Rubio E, Casado A, Valverde JJ, García Urra D, López Martín JA. Prednimustine-induced myoclonus. A report of three cases. Acta Oncol 33: 81-82, Sastre J, Martín M, Díaz-Rubio E, González Larriba JL, Casado A, Domínguez S, and López-Vega JM. Aztreonam in association with piperacillin as an empirical antibiotic treatment in febrile granulocytopenic patients with solid tumors. Oncolgy Reports 1: , García-Conde J (1), Lluch A (1), Martín M (2), Casado A (2), Gervasio H (3), De Oliveira C (3), De Pablo JL (4), Gorostiaga J (4), Girón GC (5), Cervantes A (1), Martínez A (6), Pezous N (6), Delgado FM (6) and Díaz- Rubio E (2). Phase II trial of weekly i.v. vinorelbine in first line advanced breast cancer chemotherapy. (1) H. Clínico Universitario de Valencia. (2) H. Clínico Universitario de Madrid. (3) Hospitais de Universidade, Instituto de Oncología, Coimbra, Portugal. (4) H. Txagorritsu, Vitoria, Spain. (5) H. General Yagüe, Burgos, Spain. (6) Pierre Fabre Research Centre. Annals of Oncology 5: , Martín M (1), Lluch A (2), Casado A (1), Santabárbara P (3), Adrover E (1), Valverde JJ (1), López-Martín JA (1), Rodríguez Lescure A (1) García-Conde J (2) y Díaz-Rubio E (1). Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. University Hospitals of Madrid (1) and Valencia (2), and Bristol- Myers Squibb (3), Spain. Journal of Clinical Oncology Vol 12, No 5, 1994, pp Díaz-Rubio E, MD, PhD, Martín M, MD, PhD, López-Vega JM, MD, Casado A, MD, Benavides A, MD*. Medical Oncology Department, San Carlos University Hospital, Madrid. Laboratorios Knoll, SA, Madrid. Phase I study with Mitonafide with a 3-day administration schedule: early interruption due to severe central nervous system toxicity. Investigational New Drugs 12: , Bohn U*, González JL, Martín M, Casado A, Díaz-Rubio E & Aragoncillo P. Meningeal and brain metastases in primary malignant pericardial mesothelioma. Letters to the editor: Meningeal and brain metastases in primary malignant pericardial mesothelioma. Annals of Oncology, Vol 5, Nº7, 1994, pp Sastre J, Díaz-Rubio E, Alonso MC, González ML, Martín M, González Larriba JL and Casado A. Neutropenic enteritis: A two case report and literatura review. Oncology reports 1: , Barnadas A, Mendiola C, Casado A, et al. Combination of oral idarubicin and prednimustine in advanced breast cancer. European Journal of Cancer 33 (2): , Martín M*, Aranda E, Díaz-Rubio E*, Casado A*, Rubio Mª J, Valverde JJ*, López Martín JA*, Lescure AR*, Barneto IC and González R. Emetic control in breast cancer patients receiving i.v. CMF: Results of two consecutive studies using a new method of assessment * Servicio de Oncología Médica, San Carlos University Teaching Hospital, Madrid, and Servicio de Oncología Médica, Hospital Reina Sofía, Córdoba, Spain. Oncology Reports 3: , Fernández-Marcos A, Martín M, Sánchez JJ, Rodríguez-Lescure A, Casado A, López-Martín JA, Díaz-Rubio E. Acute and anticipatory emesis in breast cancer patients Support Care Cancer, 4: , Antonio Casado (1), Rafael Rosell (2), Ramón García-Gómez (3), Eduardo Díaz-Rubio (1), Gumersindo Pérez-Manga (3), Ana Benavides (4) and Miguel Martín (4). (1) University Hospital, Madrid. (2) University Hospital, Badalona. (3) Community Hospital, Madrid. (4) Knoll Laboratories, S.A. Madrid. Spain. Phase II study of Mitonafide in non-small cell lung cancer (NSCLC). Investigational New Drugs 14: , Martín M, Casado A, López-Martín JA, Rodríguez-Lescure, Nieto Y, Ayala F, Díaz-Rubio E. UFT/Methotrexate/Leucovorin for breast cancer patients in progression after HDCT/PBPC support. Oncology, 11 (9) (Supplement 10). 1997; pp Cervantes, A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda

7 CURRICULUM VITAE Page 7 of 12 A, Benito D. Dose escalated Paclitaxel in 1-hour infusion with a fixed dose of Cisplatin in previously untreated advanced ovarian cancer: A phase II trial of the Spanish Group for Ovarian Cancer. Seminars in Oncology, vol 24, Nº 5, Suppl 15 (October), 1997: pp S15-S15-S Buesa JM, López-Pousa A, Martín J, Antón A, García del Muro J, Bellmunt J, Arranz F, De Andrés, L, Escudero P, Poveda A, Casado A. Phase II trial of first line high dose ifosfamide in advanced soft tissue sarcomas of the adult. A study of the Grupo Español de Investigación en Sarcomas. Ann Oncol 1998; 9: Buesa JM, Fra J, Antón A, López-Pousa A, Martín J, García del Muro J, Escudero P, Casado A. Activity of doxorubicin after high dose ifosfamide in adult patients with advanced soft tissue sarcoma. A study of the Grupo Español de Investigación en Sarcomas. Annals of Oncology 1998; 9: García-Patiño, E, Gomendio B, Silva JM, García JM, Provencio M, Pérez-Carrión R, Lianes P, Casado A, España P, Bonilla F. Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives. International journal of Oncology 1998; 13: Martín M, Casado A, Llorente L, García-Carbonero I, García Sáenz JA and Díaz-Rubio E. Long-term diseasefree survival in disseminated breast cancer patients treated with conventional and high-dose chemotherapy: Predictive factors and therapeutic implications. In: Veronesi U, Aapro MS and Rosti G (eds). Dose and timing: The pillars of successful chemotherapy. ESO Scientific Updates, vol 3. Elsevier Science 1998; pp Nieto Y, Martín M, Alonso JL, Casado A, Ayala F, López-Martín JA, Rodriguez-Lescure A, Díaz-Rubio E. Weekly continuos infusion of 5-Fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistence to doxorubicin. Breast Cancer Research and Treatment 1998; 50: Martín M, Alfonso R, Casado A, Oruezabal M, García Sáenz JA, García Carbonero I, Díaz-Rubio E. MUL CT (methotrexate, UFT, leucovorin) for breast cancer patients (BCP) in progression after high-dose chemotherapy and PBPC support (HDCT-PBPC). Breast Cancer Research and Treatment 1998; 50 (3): Jara C, Martín Jimenez M, Alonso C, García-Carbonero I, Fernández A, Casado A, Gómez-Aldaraví L, Pelegrí A, López-Vega JM, Batista N, Cuevas JM, González-Mancha MR, Menendez MD, Alba E, Anton A, Cassinello J, Balil A. Grupo GEICAM. Spain. Phase II trial of vinorelbine (VNB) in 96-hours continuos infusion (CI) in metastatic breast cancer refractory to anthracyclines. Breast Cancer Research and Treatment 1998; 50 (3): Martín M, Casado A, Pérez-Segura P, García Carbonero I, Díaz-Rubio E, Lluch A, García Conde J. Paclitaxel plus vinorelbine in metastatic breast cancer patients with contraindications to receive anthracyclines. Oncology 1998; 12 (Suppl.1) (1): M. Martín, A. Casado, A. Benavides, JL Alonso, I. García Carbonero, J. Sastre, E. Moreno, E. Díaz-Rubio. Phase I study of Elinafide in solid tumors. Annals of Oncology 1998; (9)(Suppl 2): Nieto Y, Alonso JA, Ayala F, Ortega L, Casado A, Martín M, Díaz-Rubio E. End stage acute hepatic failure as clinical presentation of liver metastases from breast cancer. Tumori 85(5): , J. Cuesta, L. Llorente, J. Díaz-Mediavilla, A. Álvarez, E. Del Potro, R. Martínez, A. González, A. Villegas, A. Casado, M. Martín y C. Fernández. Characteristics of the mobilization and transplant of CPSP mobilized with G-CSF in different onco-haematological diseases. Haematologica, Journal of Haematology 1998; 83 (supl.2): I. García-Carbonero, A. Casado, M. Martín, et al. DICEP high dose (HD-DICEP) chemotherapy (CT) with or without peripheral blood stem cell support as consolidation treatment of patients (pts) with advanced epithelial ovarian cancer (AOC). The European Journal of Cancer 1999; 35 (suppl.4): S M. Martín, I. García-Carbonero, A. Casado, M. Oruezabal, JA Macias, J. A. García Sáenz, I. Manrique, E. Díaz- Rubio. Weekly taxol plus navelbine in metastatic breast cancer patients (MBCP) with prior doxorubicin treatment. Breast Cancer Research and Treatment, vol 57 (1) 1999; p M. Martín, A. Lluch, A. Casado, I. García-Carbonero, L. de Paz, C. Esteban, A. Insa, R. Alfonso, J. García-Conde, E. Díaz-Rubio. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior

8 CURRICULUM VITAE Page 8 of 12 anthracycline exposure. Annals of Oncology 2000; 11: Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massuti B, H, Cortés-Funes, Lloveras B. Circulating HER-2 extracellular domain and ressitance to chemotherapy in advanced breast cancer. Clinical Cancer Research 2000; 6: Lluch A, Ojeda B, Barnadas A, Colomer R, Massuti B, Casado A, Angeles C, Maroto P. Paclitaxel and doxorubicin combination in advanced breast cancer: importance of prior adjuvant anthracycline therapy. Cancer 2000; 89: Martín M, Casado A, Macias JA, García-Carbonero I, García-Sáenz JA, Oruezabal M, Manrique I, Díaz-Rubio E. Methotrexate, Uracil and Tegafur, and leucovorin chemotherapy for patients with breast cancer in progression after high-dose chemoltherapy with peripheral blood progenitor cell transplant. A phase II study. Am J Clin Oncol 2000; 23(6): J.J Valverde, M. Martín, JA Gª Asenjo, A. Casado, JA Vidart, V. Furio, A. Pelayo, MA Herraíz, E. Díaz-Rubio. Prognostic value of DNA Quantification in early epithelial ovarian carcinoma. Obstetrics & Gynecology 2001; 97: B. Ojeda, LM de Sande, A. Casado, P Merino, and MA Casado. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. British Journal of Cancer 2003; 89: M.Martín, A. Villar, A. Solé-Calvo, R. González, B. Massuti, J. Lizón, C. Camps, A. Carrato, A. Casado, MT Candel, J. Albanell, J. Aranda, B. Munarriz, J. Campbell & E. Díaz-Rubio. On behalf of the GEICAM Group (Spanish Breast Cancer Research Group), Spain. FAC (flourouacil, doxorubicin, cyclophosphamide) versus CMF (cyclophosphamide, methotrexate, florouracil) as adjuvant chemotherapy for operable breast cancer. Annals of Oncology 2003; 14: M. Martin, M.Spielman, M. Namer, A.du Bois, C. Unger, D. Dodwell, P. Vodvarka, M. Lind, H. Calvert, A. Casado, L. Zeleck, A. Lluch, E. Carrasco, L. Kayitalire & C. Zielinski. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Annals of Oncology 2003; 14: Carlos Jara-Sánchez, Miguel Martín, Jose A. García-Sáenz, Agustí Barnadas, Antonio Fernandez-Aramburo, José M. Lopez-Vega, Amadeu Pelegrí, Emilio Alba, Antonio Casado. On behalf of the GEICAM group. Vinorelbine as 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative Study by the GEICAM Group. Clinical Breast Cancer 2003; 3 (6): Miguel Martin, Jésus García Donas, Antonio Casado, Isabel de la Gándara, Pedro Pérez Segura, José Angel García Sáenz, Gabriel Ibañez, Belen Loboff, Gemma García-Ledo, Fernando Moreno, Enrique grande, Eduardo Díaz-Rubio. Phase II study of pegylated Liposomal Doxorubicin plus Vinorelbine in Breast Cancer with Previous Anthracycline Exposure. Clinical Breast Cancer 2004; 5 (5): Joan Maurel, Joaquin Fra, Antonio López-Pousa, Xavier García del Muro, Carmen Balaña, Antonio Casado, Javier Martín, javier Martinez-Trufero, Ramón de las Peñas, José María Buesa. Sedquential Dose-Dense Doxorubicin and ifosfamide for advanced soft tissue sarcomas. A phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer 2004; 100: Joan Maurel, José Buesa, Antonio López-Pousa, Xavier García del Muro, María Jesús Quintana, Javier Martín, Antonio Casado, Javier Martínez-Trufero, Ramón de las Peñas and Carmen Balaña. Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias-a study of the Spanish Group for Research on Sarcomas (GEIS). J Surg Oncol 2004; 88: Emilio Alba, Miguel Martin, manuel Ramos, Encarna Adrover, Ana balilo, Carlos Jara, Agustí Barnadas, Antonio Fernández-Aramburu, Pedro Sanchez-Rovira, Margarita Amenedo y Antonio Casado. Multicenter randomized trial comparing sequential with concomitant administration of Doxorubicin and Docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903). J Clin Oncol 2004; 22:

9 CURRICULUM VITAE Page 9 of Clara Sanz, Fernando Moreno, Alvaro Armas, Antonio Casado and MC Castillo. Groin angiosarcoma following radiotherapy for vulvar cancer. Gynecologic Oncology 2005; 97: AJ González-Martín, E.Calvo, I. Bover, MJ Rubio, A. Arcusa, A. Casado, B. Ojeda, C.Balaña, E. Martinez, A. Herrero, B. Pardo, E. Adrover, J. Rifá, MJ Godes, A. Moyano, A.Cervantes. Randomized phase II trial of carboplatin vedrsus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de investigación en Cáncer de Ovario) Study. Annals of Oncology 2005; 16: Nicholas S Reed, Antonio Casado. European Collaborative Approach to Gynaecological Cancer Management. Business Briefing: European Pharmacotherapy 2005; Xavier García del Muro, Antonio López Pousa, Javier Martin, José María Buesa, Javier Martínez Trufero, Antonio Casado, Andrés Poveda, Josefina Cruz, Isabel Bover, Joan Maurel. Phase II trial of temozolamide as a 6 week continuous ofral schedule in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) Study. Cancer 2005; 104: José A. García Sáenz, Miguel Martín, Javier Puente, Sara López-Torruella, Antonio Casado, Fernando Moreno, Enrique Grande, Eduardo Díaz-Rubio. Trastuzumab associated with successive cytotoxic therapies beyond disease progresión in metastatic breast cancer. Clin Breast Cancer 2005; 6(4): Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, Gracía del Muro J, Maurel J, Calabuig S, Gutierrez A, González de Sande JL, Martinez J, De Juan A, Laínez N, Ferrán L, Alija V, Escudero P, Casado A, García P, Blanco R, and Buesa JM. Deletions affecting codons of the c-kit gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Researh (GEIS). Journal of Clinical Oncology 2005; 23: Poveda A, A. López-Pousa, J. Martín, J. García del Muro, R. Bernabé, A.Casado, C.Balaña, O. San Martín, M.D. Menéndez, P. Escudero, J. Cruz, Elena Belyakova, D. Menéndez & J.M. Buesa. Phase II clinical trial with pegylated liposomal doxorubicin (Caelyx/Doxil) and quality of life evaluation (EORTC QLQ-C-30) in adult patients with advanced soft tissue sarcomas. A study of the Spanish Group for Research in Sarcomas (GEIS). Sarcoma 2005; 9 (3-4): G. Stuart, E. Avall-Lundqvist, A. du Bois, M. Bookman, D. Bowtell, M. Brady, A. Casado, A. Cervantes, E. Eisenhauer, M. Friedlander, K. Fujiwara, S. Grenman, JP Guastalla, P. Harper, T. Hogberg, S. Kaye, H. Kitchener, G. Kristensen, R. Mannel, W. Meier, B. Miller, A. Oza, R. Ozols, M. Parmar, J. Pfisterer, A. Poveda, D. Provencher, E. Pujade-Lauraine, M. Quinn, M. Randall, J. Rochon, G. Rustin, S. Sagae, F. Stehman, E. Trimble, T. Thigpen, P. Vasey, I. Vergote, R. Verheijen, J. Vermorken, U. Wagner. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Annals of Oncology 2005; 16 (Suppl 8):viii36-viii A. Du Bois, M. Quinn, T. Thigpen, J.B. Vermorken, E. Avall-Lundqvist, M. Bookman, D. Bowtell, M. Brady, A. Casado, A. Cervantes, E. Eisenhauer, M. Friedlander, K. Fujiwara, S. Grenman, JP Guastalla, P. Harper, T. Hogberg, S. Kaye, H. Kitchner, G. Kristensen, R. Mannel, W. Meier, B. Miller, JP Neijt, A. Oza, R. Ozols, M. Parmar, S. Pecorelli, J. Pfisterer, A. Poveda, D. Provencher, E. Pujade-Lauraine, M. Randall, J. Rochon, G. Rustin, S. Sagae, F. Stehman, G. Stuart, E. Trimble, P. Vasey, I. Vergote, R. Verheijen, U. Wagner consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annals of Oncology 2005; 16 (Suppl. 8):viii7-viii M. Quinn, J. Pfisterer, E. Avall-Lundqvist, M. Bookman, D. Bowtell, A. Casado, A. Cervantes, S. Grenman, P. Harper, A. Oza, S. Pecorelli, E. Pujade-Lauraine, E. Trimble, P. Vasey and U. Wagner. Integration of new or experimental treatment options and new approaches to clinical trials. Annals of Oncology 2005; 16 (Suppl. 8): viii30-viii35.

10 CURRICULUM VITAE Page 10 of A. López-Pousa, R. Losa, J. Martín, J. Maurel, J. Fra, M. Sierra, A. Casado, J. García del Muro, A. Poveda C. Balaña, J. Martinez-Trufero, E. Esteban and JM Buesa. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas. A GEIS study. British Journal of Cancer 2006; 19; 94(12): (online publication 23 May 2006;doi: /sj.bjc ). 60. A. López-Pousa, J. Martín, J. Montalar, R. de las Peñas, J. García del Muro, J. Cruz, J. laurel, P. Escudero, A. Casado, J.M. Buesa, and the Spanish Group for Research on Sarcomas (GEIS). Phase II trial of Doxorubicin plus escalated high-dose ifosfamide in patients with advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS). Sarcoma 2006 (Sept 19): 1-8 (article ID 26986). 61. Javier Puente Vázquez, Sara López-Tarruella Cobo, Fernando Moreno Antón, Antonio Casado Herráez, José Antonio Vidart, Pluvio Coronado, Eduardo Díaz-Rubio. Brain metastasis and carcinomatous meningitis from vulvar squamous cell carcinoma: case report. European Journal of Gynaecological Oncolgy 2007 (2): Casado, A, Reed, N. Treatment strategies for ovarian cancer. Touch Briefing. European Oncological Disease 2006 (in press). 63. Marth C, Walker JL, Barakat RR, Casado A, Gadducci A, Miller B, Odicino F, Pujade-Lauraine E, Sehouli J, Tropé C, Wenzel L, Zeimet AG. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 2007; (109): Miguel Martín, Amparo Ruiz, Monserrat Muñoz, Ana Balil, Jesús García Mata, Lourdes Calvo, Eva Carrasco, Esther Malillo, Antonio Casado, José Angel García-Sanz, M José Escudero, vicente Guillem, Carlos Jara, Nuria Ribelles, Fernando Salas, Celia Soto, Flavia Morales-Vasquez, César A. Rodríguez, Encarna Adrover, José Ramón Mel. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.lancet Oncol 2007; 8: José A García-Sáenz, Miguel Martín, Antonio Calles, Coralia Bueno, Laura Rodriguez, Jana Bobokova, Ana Custodio, Antonio Casado and Eduardo Díaz-Rubio. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline and taxane-refractory breast cancer. J Chemother Oct;20 (5): Ojeda, G B, González Martín, A, Bover Barcelo I, Fabregat i Mayol, I, Mellado B, Rubio Pérez, MJ, Alonso Carrión L, Casado Herráez, A, Calvo García, E, Churruca Galaz, C, Arcusa Lanza, A, Herrero Ibañez, A, Adrover Cebrián, E, Poveda Velasco, A. A phase II trial of fixed-dosed rate gemcitabine in platinumresistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial. Am J Clin Oncol 2008; Oct; 31 (5): Martín-Broto J, Gutierrez A, García del Muro X, López-Guerrero JA, Martínez-Trufero J, de Sande LM, Laínez N, Maurel J, de Juan A, Losa F, Andrés R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gómez- España A, Ramos R, Martínez-Serra J, Llombart Bosch A, Poveda A. Prognostic time dependence of deletions affecting codón 557 and/ or 558 of KIT gene for relapse-free survival (RFS) in localizaed GIST: A Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 2010; Jul 21 (7): Epub 2010 Mar Miguel Martín, José Angel García Sáenz, Maria Luisa Maestro de las Casas, Marta Vidaurreta, Javier Puente, Silvia Veganzones, Laura Rodriguez Lajusticia, Virginia de la Orden, Belen Oliva, Julio césar de la Torre, Sara López Tarruella, Antonio Casado, Javier Sastre and Eduardo Díaz-Rubio. Circulating tumour cells in metastatic breast cáncer: timing of blood extraction for analysis. Anticancer Research 2009; 29: Del Campo JM, Roszak A, Bidzinski M, Ciuleanu TE, Hogberg T, Wocjtukiewitz MZ, Poveda A, Boman K, Westermann AM, Lebedinsky C, Yondelis Ovarian Cancer Group (*). Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to

11 CURRICULUM VITAE Page 11 of 12 patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20 (11): (*) Author collaborator: A Casado. 70. Joan Maurel, Ana Sofia Martins, Andrés Poveda, Ricardo Cubedo, Antonio Casado, Javier Martínez-Trufero, Juan Ramóin Ayuso, Antonio López-Pousa, Xabier García -Albeniz, Xavier García del Muro and Enrique de Alava. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumours refractory to high-dose imatininb: A phase I-II study by the Spanish Group for Research on Sarcomas. Cancer 2010 Apr 29 (DOI: /cncr.25111). 71. Ignace Vergote, Eric Pujade-Lauraine, Sandro Pignata, Gunnar Kristensen, Jonathan Ledermann, Antonio Casado, Jalid Sehouli, Maansor Mirza, Roldano Fossati, Christian Marth, Carine Creutzberg, Jose del Campo, Nadeem Siddiqui, Paula Calvert, Aris Bamias, Gokhan Tulunay, Ate van der Zee and Andreas du Bois on behalf of the member trial groups of European Network of Gynaecology Oncological Trial Groups (ENGOT). European Network of Gynaecological Oncological Trial Group s Requirements for Trials between Academic Groups and Pharmaceutical Companies. Int J Gynecol Cancer 2010; 20: Alba E, Ruiz-Borrego M, Margelí M, Rodriguez-Lescure A, Sánchez-Rovira P, Ruiz A, Mel-Lorenzo JR, Ramos-Vázquez M, Ribelles N, Calvo E, Casado A, Marquez A, Vicente D, García Sáenz JA, Martín M. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cáncer: GEICAM study. Breast Cancer Research Treatment 2010; 122 (1): Baptist Trimbos, Petra Timmers, Sergio Pecorelli, Corneel Coens, Koen Ven, Maria van der Burg, Antonio Casado. Surgical staging and treatment of early ovarían cáncer: long-term analysis from a randomized trial. J Natl Cancer Inst 2010; 102: Ignace Vergote, Claes G. Tropé, Frederic Amant, Gunnar B. Kristensen, Tom Ehlen, Nick Johnson, René HM Verheijen, Maria E.L. van der Burg, Angel J. Lacave, Pierluigi Benedetti Panici, Gemma G. Kenter, Antonio Casado, César Mendiola, Corneel Coens, Leen Verleye, Gavin CE Stuart, Sergio Pecorelli, and Nick Reed, for the European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group and the NCIC Clinical Trials Group- A Gynecologic Cancer Intergroup Collaboration. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New England Journal of Medicine 210; 363: Ignace Vergote, Corneel Coens, Antonio Casado. Neoadjuvant Chemotherapy or Primary Surgery in Advanced Ovarian Cancer. Authors reply. New England Journal Medicine Dec 9; 363 (24): M. Martin, P. Sánchez-Rovira, M. Muñoz, J.M. Baena-Cañada, J.R. Mel, M. Margeli, M. Ramos, E. Martínez, J. A. García-Sáenz, A. Casado, A. M. Jaén, X. González-Farré, M.J. Escudero, C. Rodiriguez-Martín & E. Carrasco on behalf of GEICAM. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER-2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/ study. Annals of Oncology (advance Access published March 17, 2011). 77. Gordon JS Rustin, Maria EL van der Burg, Clare L Griffin, David Guthrie, Alan Lamont, Gordon C Jayson, Gunnar Kristensen, César Mendiola, Corneel Coens, Wendi Qian, Mahesh KV Parmar, Ann Marie Swart, for the MRC OV05 and EORTC investigators (*). Early versus delayed treatment of relapsed ovarian cancer (MRC OV05 / EORTC 55955): a randomized trial. Lancet 2010; 376: (*) Author collaborator: A. Casado Herráez 78. Anton A, Lluch A, Casado A, Provencio M, Muñoz M, Lao J, Bermejo B, Paules AB, Gayo J, Martin M. Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer. Anticancer Research 2010; 30 (6):

12 CURRICULUM VITAE Page 12 of Paz-Ares L, López-Pousa A, Poveda A, Balaña C, Ciruelos E, Bellmunt J, Del Muro JG, Provencio M, Casado A, Rivera-Herrero F, Izquierdo MA, Nieto A, Tanovic A, Cortés-Funes H, Buesa JM. Trabectedin in pretreated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs 2010; Oct 20 (Epub ahead of print). 80. Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martinez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel JF, F Pons F. Q J Nucl Med Mol Imaging 2010 Dec 9 (Epub ahead of Print). 81. Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, Poveda A, Provencher D, Katsaros D, Ojeda D, Ghataje P, Grimshaw R, Casado A, Elit L, Mendiola C, Sugimoto A, D Hondt V, Oza A, Germa JR, Roy M, Brotto L, Chen D, Eisenhauer EA. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel versus carboplatin-paclitaxel. J Natl Cancer Inst 2010; 102 (20): Martin M, Romero A, Cheang MC, López García-Asenjo JA, García Sáenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Cáldes T, Vidart JA, López-Tarruella S, Díaz-Rubio E, Perou CM. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 2011 April 5 (Epub ahead of print).

Sarcoma Research Group Group leader: Òscar Martínez Tirado

Sarcoma Research Group Group leader: Òscar Martínez Tirado Sarcoma Research Group Group leader: Òscar Martínez Tirado IDIBELL since 2007 Miguel Servet program (Fondo de Investigaciones Sanitarias) 2009 Sarcoma Research Group (SGR682) Group leader: Òscar Martínez

More information

Academic Research in Europe Dra. Eva Carrasco

Academic Research in Europe Dra. Eva Carrasco Academic Research in Europe Dra. Eva Carrasco Scientific Director Spanish Breast Cancer Research Group Type of clinical trials Type 1: Designed and sponsored by the Pharmaceutical Industry, proposed to

More information

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage

More information

Management of Platinum-Sensitive Recurrent Ovarian Cancer

Management of Platinum-Sensitive Recurrent Ovarian Cancer Management of Platinum-Sensitive Jacobus Pfisterer a and Jonathan A. Ledermann b The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line surgery and chemotherapy.

More information

REVIEW ARTICLE. Key Words: CA 125, Ovarian cancer, Response, Progression, RECIST, Clinical trials

REVIEW ARTICLE. Key Words: CA 125, Ovarian cancer, Response, Progression, RECIST, Clinical trials REVIEW ARTICLE Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG) Gordon John Sampson Rustin,

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

U.S. Food and Drug Administration

U.S. Food and Drug Administration U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

More information

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

EORTC Gynecological Cancer Group (GCG) Meeting

EORTC Gynecological Cancer Group (GCG) Meeting EORTC Gynecological Cancer Group (GCG) Meeting VENUE : HOTEL SANTA CATALINA. LEÓN Y CASTILLO, 227. 35005 LAS PALMAS DE GRAN CANARIA RECOMMENDED HOTEL: SANTA CATALINA (HTTP ://WWW.HOTELSANTACATALINA.COM).

More information

Cytotoxic Therapy in Metastatic Breast Cancer

Cytotoxic Therapy in Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Cytotoxic Therapy in Metastatic Breast Cancer Version 2002: von Minckwitz Versions

More information

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment.

Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. 1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300

More information

Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO)

Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO) Under the Auspices of Organized by 10th International Symposium Advanced Ovarian Cancer: Optimal Therapy. Update Valencia, Spain, 6th March 2015 Directors Andrés Poveda Fundación Instituto Valenciano de

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the

More information

with ovarian cancer exhibit an initial response. 5 In addition, the majority of

with ovarian cancer exhibit an initial response. 5 In addition, the majority of Research ONCOLOGY Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer Laura J. Havrilesky, MD, MHSc; Thomas C. Krivak, MD; John W. Mucenski, PharmD; Evan R. Myers, MD, MPH OBJECTIVE:

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

Wednesday, February 24 th, 2016

Wednesday, February 24 th, 2016 List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University

More information

E UROPEAN CURRICULUM VITAE FORMAT

E UROPEAN CURRICULUM VITAE FORMAT E UROPEAN CURRICULUM VITAE FORMAT PERSONAL INFORMATION Name Address VALENTINA GUARNERI University of Padova Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche Istituto Oncologico Veneto

More information

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen. Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell

More information

Updated: 18/2/2015 PERSONAL PROFILE

Updated: 18/2/2015 PERSONAL PROFILE Carlos J. Perez del Pulgar Escuela de Ingenierías C/Ortiz Ramos s/n 29071 Málaga (Spain) Landline: +34 951952324 Email: carlosperez@uma.es www.isa.uma.es/cperez Updated: 18/2/2015 PERSONAL PROFILE Since

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab

Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation

Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation PharmaMar announces new advances in oncology at ASCO 2015 for its compounds YONDELIS and PM1183 in small cell lung cancer, soft tissue sarcoma, and mesothelioma Compelling clinical activity of PM1183 in

More information

Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer. Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK

Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer. Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK Selecting Second Line Treatment for Relapsing Epithelial Ovarian Cancer Dr. Rebecca Kristeleit Prof. Jonathan Ledermann UCL, London, UK Overview of Presentation This presentation will discuss the management

More information

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)

More information

Biomedicine The background. The main interest. The tools

Biomedicine The background. The main interest. The tools 1 Biomedicine The background The main interest? Bioinformatics Clinical informatics The tools 2 Outline 3 Outline 4 Working on Network Data Analysis HH RR Infrastructure Training BIOCOMPUTATION & STRUCTURAL

More information

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine

BREAST CANCER - METASTATIC & LOCALLY ADVANCED CHEMOTHERAPY REGIMENS Capecitabine. Capecitabine + Docetaxel. Capecitabine + Vinorelbine Capecitabine Capecitabine 1000-1250mg/m 2 oral TWICE daily for 14 days Until disease progression Capecitabine + Docetaxel Capecitabine 750-1000mg/m 2 oral TWICE daily for 14 days Up to 6 cycles Capecitabine

More information

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient

Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

ADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT

ADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT te: Consider Clinical Trials as treatment options for eligible patients. Referral to a center with both pediatric oncology and orthopedic surgery is essential. CLINICAL EVALUATION This practice algorithm

More information

Small-Cell Lung Cancer: Is There a Standard Therapy?

Small-Cell Lung Cancer: Is There a Standard Therapy? Small-Cell Lung Cancer: Is There a Standard Therapy? Review Article [1] January 02, 1998 By Pieter E. Postmus, MD, PhD [2] and Egbert F. Smit, MD [3] For more than 25 years, chemotherapy has been the cornerstone

More information

The Impact of Taxotere on Adjuvant Breast Cancer

The Impact of Taxotere on Adjuvant Breast Cancer The Impact of Taxotere on Adjuvant Breast Cancer a report by Pierre Fumoleau and Henri Roché Centre Georges François Leclerc, Dijon, and Institut Claudius Regaud, Toulouse, France DOI: 10.17925/EOH.2005.0.0.1l

More information

Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer

Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer REVIEW ARTICLE Adjuvant Chemotherapy After Complete Resection of Non-Small Cell Lung Cancer Eckart Laack, Carsten Bokemeyer, Dieter Kurt Hossfeld SUMMARY Introduction: In non-small cell lung cancer (NSCLC)

More information

Updated: 6/10/2015 PERSONAL PROFILE

Updated: 6/10/2015 PERSONAL PROFILE Carlos J. Pérez del Pulgar Escuela de Ingenierías C/Ortiz Ramos s/n 29071 Málaga (Spain) Landline: +34 951952324 Email: carlosperez@uma.es www.isa.uma.es/cperez Updated: 6/10/2015 PERSONAL PROFILE Since

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Local Courses s REPORT

Local Courses s REPORT Project cofinanced by European Regional Development Fund Project cofinancé par le Fonds européen de développement régional 1G-MED08-515 Sustainable Water Management through Common Responsibility enhancement

More information

EPITHELIAL OVARIAN CANCER

EPITHELIAL OVARIAN CANCER EPITHELIAL OVARIAN CANCER Executive Summary Epithelial ovarian cancer is the most common type of ovarian cancer and the most aggressive gynecological malignancy. Approximately 70% of patients are diagnosed

More information

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2

Schedule: Drug Dose iv/infusion/oral q Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 Doxorubicin/Cisplatin Osteosarcoma - neoadjuvant Doxorubicin 25mg/m 2 iv bolus Days 1, 2 & 3 Cisplatin 50mg/m 2 1L N. Saline/2hrs Days 1 & 2 (3 before surgery) Ensure adequate renal function Pre & post-hydration,

More information

2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer

2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer REVIEW ARTICLE 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report From the Fourth Ovarian Cancer Consensus Conference Gavin C.E. Stuart, MD, FRCSC,*

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

Optimal treatment of early-stage ovarian cancer

Optimal treatment of early-stage ovarian cancer Annals of Oncology Advance Access published March 14, 2014 1 Optimal treatment of early-stage ovarian cancer F. Collinson *,1, W. Qian *,2, R. Fossati 3, A. Lissoni 4, C. Williams 5, M. Parmar 6, J. Ledermann

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Focus on IBD

Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Focus on IBD Marbella (Spain), January 29th & 30th, 2015 Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Preliminary Program Thursday, January 29th 2015 15:45-16:00 Welcome to the

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

Wednesday, February 24 th, 2016

Wednesday, February 24 th, 2016 List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University

More information

First-line chemotherapy for women with epithelial ovarian cancer

First-line chemotherapy for women with epithelial ovarian cancer First-line chemotherapy for women with epithelial ovarian cancer A systematic review July 2013 First line chemotherapy for women with epithelial ovarian cancer: a systematic review was prepared and produced

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer

Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone

More information

REPORT AT 30 SEPTEMBER 2014 9M 2014 MILESTONES

REPORT AT 30 SEPTEMBER 2014 9M 2014 MILESTONES REPORT AT 30 SEPTEMBER 2014 Madrid, 30 October 2014 Group 9M 2014 MILESTONES Zeltia Group s net sales amounted to 116.9 million euro (+7%). Yondelis accounted for 57.4 million euro (+8%). Consumer Chemicals

More information

Cycle frequency: Every three weeks Total number of cycles: 6

Cycle frequency: Every three weeks Total number of cycles: 6 Carboplatin/Paclitaxel Ovarian Cancer Adjuvant, Advanced Paclitaxel 175mg/m 2 500mls 5% dex/3hrs Day 1 Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Anti-emetic group - Moderately high Paclitaxel given first

More information

First-line chemotherapy for the treatment of women with epithelial ovarian cancer

First-line chemotherapy for the treatment of women with epithelial ovarian cancer First-line chemotherapy for the treatment of women with epithelial ovarian cancer Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer June 2014

More information

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of

More information

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase

More information

The role of PARP inhibitors in high grade serous ovarian cancers

The role of PARP inhibitors in high grade serous ovarian cancers The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Network Chemotherapy Regimens

Network Chemotherapy Regimens Network Chemotherapy Regimens Lung Cancer Notes from the editor Thames Valley Cancer Network These protocols are available on the Network website www.tvcn.org.uk. Any correspondence about the protocols

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

Telefónica S.A. MANAGEMENT

Telefónica S.A. MANAGEMENT Telefónica S.A. MANAGEMENT Board of Directors Members at the date of publication of this Annual Report (1) Chairman and Chief Executive Officer Vice-Chairmen Mr. Isidro Fainé Casas Mr. Pedro Luis Uriarte

More information

trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd

trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd 06 December 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

London Cancer. Mesothelioma Lung Protocols

London Cancer. Mesothelioma Lung Protocols London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta

More information

About chemotherapy for lung cancer

About chemotherapy for lung cancer About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

More information

Access to hormone receptor testing and other basic diagnostic pathology services in Colombia

Access to hormone receptor testing and other basic diagnostic pathology services in Colombia Access to hormone receptor testing and other basic diagnostic pathology services in Colombia Dr Fernando Perry Clínica de seno y tejidos blandos Instituto Nacional de Cancerología de Colombia Breast cancer

More information

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

Osteosarcoma: treatment beyond surgery

Osteosarcoma: treatment beyond surgery Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma

More information

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

Gynäkologische Onkologie-Klinische Studien

Gynäkologische Onkologie-Klinische Studien Gynäkologische Onkologie-Klinische Studien Breast cancer A randomized, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information

What is the reference cytotoxic regimen in advanced gastric cancer?

What is the reference cytotoxic regimen in advanced gastric cancer? What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.

More information

Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer

Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Policy Number: Original Effective Date: MM.07.014 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 01/23/2015 Section:

More information

GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE

GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE Personal Information Date of birth July 2, 1953 Place of birth Torino, Italy Office address Department of Oncology S. Luigi Gonzaga Hospital, Oncology

More information

Nonanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer

Nonanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer nanthracycline Containing Docetaxel-Based Combinations in Metastatic Breast Cancer JOHN CROWN St. Vincent s Hospital, Dublin, Ireland Key Words. MBC Docetaxel Cisplatin Carboplatin Vinorelbine Gemcitabine

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1 COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize

More information

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8

Schedule: Drug Dose iv/infusion/oral q Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Carboplatin/Gemcitabine Lung Cancer (non-small cell) - Advanced Carboplatin AUC 5 500mls 5% dex/1hr Day 1 Gemcitabine 1200mg/m 2 200mls N. Saline/30mins Days 1 & 8 Cycle frequency: Every three weeks Total

More information

Phase III trials in oncology

Phase III trials in oncology Phase III trials in oncology Setting standards of care? Siegfried Seeber and Ada H Braun* Survival data from phase III trials can be very misleading because patients are not offered the best follow-up

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

How To Contact Cotransa

How To Contact Cotransa COTRANSA - Key Contact Details Physical address: MADRID (HEAD OFFICE) Avda Central, Parcela 2.5, Naves 1 y 3. 28042 Centro de carga aerea Marid-Barajas Madrid (SPAIN) Tel: +34 917 46 06 80 Fax: +34 913

More information

TIGRE5-CM - Presentation

TIGRE5-CM - Presentation TIGRE5-CM - Presentation The aim of TIGRE5-CM project is to design an architecture for future generation mobile networks, based on the SDN (Software Defined Networking) paradigm, which eases the deployment,

More information

Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)

Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four

More information

Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Expanding the Scope to IBD

Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Expanding the Scope to IBD Marbella (Spain), January 17th & 18th, 2013 Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Thursday, January 17th 2013 8:45-9:00 Welcome to the Hands-on Course Andres

More information

Navigating GIST. The Life Raft Group June 12, 2008

Navigating GIST. The Life Raft Group June 12, 2008 Navigating GIST Clinical Trials The Life Raft Group June 12, 2008 Some observations: Annually, only 3% of adult patients participate in cancer clinical trials. Lara et. al; Evaluation of factors affecting

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Recognizing Value in Oncology Innovation. Thomas F. Goss, PharmD, Emilie H. Picard, MS, and Andrew Tarab, MHA

Recognizing Value in Oncology Innovation. Thomas F. Goss, PharmD, Emilie H. Picard, MS, and Andrew Tarab, MHA White Paper JUNE 2012 Recognizing Value in Oncology Innovation Thomas F. Goss, PharmD, Emilie H. Picard, MS, and Andrew Tarab, MHA Boston Healthcare Associates, Inc., Boston, MA, and Washington, DC Recognizing

More information